Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, Butler J, Cherney D, Claggett B, Fletcher R, Herrington W, Inzucchi S, Jardine M, Mahaffey K, McGuire D, McMurray J, Neal B, Packer M, Perkovic V, Solomon S, Staplin N, Vaduganathan M, Wanner C, Wheeler D, Zannad F, Zhao Y, Heerspink H, Sabatine M, Wiviott S. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 2024, 149: 1789-1801. PMID: 38583093, PMCID: PMC11149938, DOI: 10.1161/circulationaha.124.069568.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter-2 inhibitorsSudden cardiac deathAtherosclerotic cardiovascular diseaseCardiovascular deathPatient populationHF deathCardiac deathReduction of cardiovascular deathTrial-level meta-analysisMyocardial infarctionCardiovascular diseaseOverall populationCotransporter-2 inhibitorsRisk of MACETrial of patientsRate of MACEIndividual components of MACEAdverse cardiovascular eventsKidney-related outcomesAll-Cause MortalityChronic kidney diseaseComponents of MACESGLT2i therapyPlacebo-ControlledClinical characteristics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply